Under a tenth of patients eligible to benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it issues its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to these injectable treatments.
Per forecasts, over two billion are projected to be living with obesity by 2030 without intervention.
"The new guidance affirms that obesity is a chronic disease that can be managed with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major barriers to widespread availability to the injections that can aid individuals in losing significant weight, says the organization.
GLP-1 Therapy Shortage
Despite the present most favorable outlook, the production of these medications might only reach approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline urges nations and manufacturers to expand availability, through strategies including voluntary licensing.
Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Jabs Operate
The injections replicate a natural hormone to slow digestion, suppress the appetite and boost satiety so people eat less.
Patients commonly see weight reduction within a few weeks of starting on the weekly injections.
Evidence suggests users may put most of the weight back on a year later of discontinuing the medication, when their typical hunger return.
Being carrying excess weight increases your likelihood for contracting diseases, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
